Vallon Pharmaceuticals Long Term Debt

Vallon Pharmaceuticals (VLON) currently reports a long-term debt of $58K as of March 2025. That compares with $110K in the prior-year period — down 46.8% year over year. Use the charts on this page to explore Vallon Pharmaceuticals's long-term debt history and peer comparisons.

Vallon Pharmaceuticals's long-term debt decreased from $110K to $58K — a 46.8% year-over-year decrease (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Vallon Pharmaceuticals reported $58K in long-term debt as of March 2025. That compares with $110K in the prior-year period — down 46.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $58K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Vallon Pharmaceuticals, and consider following VLON for alerts when major investors trade the stock.

Vallon Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $58K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VLON with unrelated industries.